VivoSeq
Oncology

Basal Cell Carcinoma

59

Pipeline Programs↗

24

Active Trials↗

28

Companies Involved↗

Basal Cell Carcinoma is a moderately active landscape with 59 programs across 28 companies. The most active players are Senhwa Biosciences, Inc., Feldan Therapeutics, Merck & Co.. 9 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

32/100

Mech. Concentration

12/100

Completion Rate

87/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Senhwa Biosciences, Inc.

1 program

Phase 1F

Feldan Therapeutics

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2A

Ascend Biopharmaceuticals Ltd

1 program

Phase 2A

AiViva BioPharma, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Cemiplimab

Regeneron

Sonidegib

Sun Pharma

Metvix

Galderma R&D

MAL-PDT Re-Treatment

Norwegian University of Science and Technology

Usual MAL-PDT

Norwegian University of Science and Technology

Phase 14

Pembrolizumab

Merck & Co.

Aminolevulinic Acid Hcl

DUSA Pharmaceuticals, Inc.

CX-4945

Senhwa Biosciences, Inc.

Intralesional FLD-103

Feldan Therapeutics

Phase 236

Calcitriol

Alnylam Pharmaceuticals

Relatlimab

Bristol-Myers Squibb

Itraconazole

Sebela Pharmaceuticals Development LLC

Diclofenac

Novartis

Nivolumab

Bristol-Myers Squibb

Phase 35

Methyl Aminolevulinate

Galderma R&D

Formulated Methylene Blue

Daryoush Hamidi Alamdari, PhD

Calcium Chloride

Pfizer

BF-200 ALA

Biofrontera Bioscience GmbH

Verteporfin PDT

Novartis

Approved9

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Vismodegib

Roche

Verteporfin

Bausch Health Americas, Inc.

Tretinoin

Valeant Pharmaceuticals

Aminolevulinic Acid

Biomed Industries, Inc.

Analysis

Modality Breakdown

89%

Small molecule

57 of 64 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody711%

Small molecule leads; the ring shows all 64 classified programs, each share of the total. Modality classified for 99% of 71 pipeline programs.

Analysis

Trial Status

101

clinical trials

Completed58 · 57%
Recruiting18 · 18%
Terminated8 · 8%
Unknown status8 · 8%
Not yet recruiting3 · 3%
Active, not recruiting2 · 2%
Other4 · 4%

Clinical Trials

Trial Activity

101 trials

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
Recruiting·IInozyme Pharma·Phase 2·NCT06462547·200 enrolled
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT06981325·34 enrolled
Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
Recruiting·TThomas Jefferson University·Phase 2·NCT05929664·70 enrolled
Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy
Recruiting·—·Phase 2·NCT05020912·28 enrolled
The Purpose of This Study is to Evaluate the Safety and Efficacy of D-MNA in Adult Patients With Nodular Basal Cell Carcinoma
Recruiting·SSkinJect, Inc.·Phase 2·NCT06608238·60 enrolled
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03521830·57 enrolled
Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas
Recruiting·—·Phase 1·NCT06623201·20 enrolled
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
Recruiting·UUniversity of California, San Diego·Phase 2·NCT06624475·30 enrolled
Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma
Recruiting·UUniversity Hospital, Lille·Phase 2·NCT05561634·82 enrolled
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Recruiting·MMaastricht University Medical Center·N/A·NCT05463757·80 enrolled
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Recruiting·SStamford Pharmaceuticals, Inc.·Phase 2·NCT06344052·80 enrolled
Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma
Recruiting·MMaastricht University Medical Center·N/A·NCT06252857·142 enrolled
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05651828·34 enrolled
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
Recruiting·MMediWound Ltd·Phase 1/2·NCT05157763·32 enrolled
Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
Recruiting·IInstituto Oncológico Dr Rosell·Phase 1/2·NCT07251413·18 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)